AU2003205664B2 - Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis - Google Patents
Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis Download PDFInfo
- Publication number
- AU2003205664B2 AU2003205664B2 AU2003205664A AU2003205664A AU2003205664B2 AU 2003205664 B2 AU2003205664 B2 AU 2003205664B2 AU 2003205664 A AU2003205664 A AU 2003205664A AU 2003205664 A AU2003205664 A AU 2003205664A AU 2003205664 B2 AU2003205664 B2 AU 2003205664B2
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- dose
- methyl
- sulfo
- tri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP002075374.5 | 2002-01-29 | ||
| EP02075374 | 2002-01-29 | ||
| PCT/EP2003/000696 WO2003063881A1 (en) | 2002-01-29 | 2003-01-23 | Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003205664A1 AU2003205664A1 (en) | 2003-09-18 |
| AU2003205664B2 true AU2003205664B2 (en) | 2008-06-05 |
Family
ID=27635850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003205664A Ceased AU2003205664B2 (en) | 2002-01-29 | 2003-01-23 | Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7709463B2 (enExample) |
| EP (1) | EP1471924B1 (enExample) |
| JP (1) | JP4870907B2 (enExample) |
| CN (1) | CN1622813A (enExample) |
| AR (1) | AR038320A1 (enExample) |
| AT (1) | ATE323497T1 (enExample) |
| AU (1) | AU2003205664B2 (enExample) |
| BR (1) | BR0307196A (enExample) |
| CA (1) | CA2472957C (enExample) |
| CY (1) | CY1107661T1 (enExample) |
| DE (1) | DE60304678T2 (enExample) |
| DK (1) | DK1471924T3 (enExample) |
| EA (1) | EA007204B1 (enExample) |
| ES (1) | ES2262971T3 (enExample) |
| MX (1) | MXPA04007310A (enExample) |
| NO (1) | NO332699B1 (enExample) |
| PE (1) | PE20030855A1 (enExample) |
| PL (1) | PL207144B1 (enExample) |
| PT (1) | PT1471924E (enExample) |
| SI (1) | SI1471924T1 (enExample) |
| TW (1) | TWI281861B (enExample) |
| WO (1) | WO2003063881A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008521903A (ja) * | 2004-12-01 | 2008-06-26 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Ｎ置換されたベンズイミダゾリルＣ−ｋｉｔ阻害剤及びコンビナトリアルベンゾイミダゾールライブラリー |
| US9642822B2 (en) | 2011-05-27 | 2017-05-09 | Children's Medical Center Corporation | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| BR112022000255A8 (pt) | 2019-07-09 | 2022-03-22 | Optimvia Llc | Métodos para sintetizar polissacarídeos anticoagulantes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378829A (en) * | 1990-04-23 | 1995-01-03 | Akzo N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type |
-
2003
- 2003-01-14 TW TW092100703A patent/TWI281861B/zh not_active IP Right Cessation
- 2003-01-23 ES ES03702514T patent/ES2262971T3/es not_active Expired - Lifetime
- 2003-01-23 AT AT03702514T patent/ATE323497T1/de active
- 2003-01-23 MX MXPA04007310A patent/MXPA04007310A/es active IP Right Grant
- 2003-01-23 WO PCT/EP2003/000696 patent/WO2003063881A1/en not_active Ceased
- 2003-01-23 EA EA200400817A patent/EA007204B1/ru not_active IP Right Cessation
- 2003-01-23 BR BR0307196-0A patent/BR0307196A/pt not_active Application Discontinuation
- 2003-01-23 DE DE60304678T patent/DE60304678T2/de not_active Expired - Lifetime
- 2003-01-23 JP JP2003563570A patent/JP4870907B2/ja not_active Expired - Fee Related
- 2003-01-23 DK DK03702514T patent/DK1471924T3/da active
- 2003-01-23 CN CNA038028123A patent/CN1622813A/zh active Pending
- 2003-01-23 PE PE2003000071A patent/PE20030855A1/es not_active Application Discontinuation
- 2003-01-23 SI SI200330334T patent/SI1471924T1/sl unknown
- 2003-01-23 PL PL370557A patent/PL207144B1/pl unknown
- 2003-01-23 CA CA2472957A patent/CA2472957C/en not_active Expired - Fee Related
- 2003-01-23 EP EP03702514A patent/EP1471924B1/en not_active Expired - Lifetime
- 2003-01-23 PT PT03702514T patent/PT1471924E/pt unknown
- 2003-01-23 AU AU2003205664A patent/AU2003205664B2/en not_active Ceased
- 2003-01-23 US US10/502,706 patent/US7709463B2/en not_active Expired - Fee Related
- 2003-01-28 AR ARP030100237A patent/AR038320A1/es not_active Application Discontinuation
-
2004
- 2004-07-27 NO NO20043195A patent/NO332699B1/no not_active IP Right Cessation
-
2006
- 2006-07-19 CY CY20061101002T patent/CY1107661T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378829A (en) * | 1990-04-23 | 1995-01-03 | Akzo N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type |
Non-Patent Citations (1)
| Title |
|---|
| Das, S. et al Chemistry - A European Journal 2001, 7(22):4821-4834 * |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20043195L (no) | 2004-10-29 |
| US20050209175A1 (en) | 2005-09-22 |
| EA200400817A1 (ru) | 2005-02-24 |
| EA007204B1 (ru) | 2006-08-25 |
| PT1471924E (pt) | 2006-09-29 |
| TWI281861B (en) | 2007-06-01 |
| CA2472957A1 (en) | 2003-08-07 |
| CY1107661T1 (el) | 2013-04-18 |
| MXPA04007310A (es) | 2004-10-29 |
| EP1471924A1 (en) | 2004-11-03 |
| DE60304678D1 (de) | 2006-05-24 |
| PL370557A1 (en) | 2005-05-30 |
| ATE323497T1 (de) | 2006-05-15 |
| CA2472957C (en) | 2011-09-13 |
| HK1072361A1 (en) | 2005-08-26 |
| WO2003063881A1 (en) | 2003-08-07 |
| US7709463B2 (en) | 2010-05-04 |
| BR0307196A (pt) | 2004-11-03 |
| AR038320A1 (es) | 2005-01-12 |
| ES2262971T3 (es) | 2006-12-01 |
| PL207144B1 (pl) | 2010-11-30 |
| SI1471924T1 (sl) | 2006-10-31 |
| PE20030855A1 (es) | 2003-10-11 |
| DE60304678T2 (de) | 2007-04-05 |
| EP1471924B1 (en) | 2006-04-19 |
| CN1622813A (zh) | 2005-06-01 |
| DK1471924T3 (da) | 2006-08-21 |
| NO332699B1 (no) | 2012-12-10 |
| JP4870907B2 (ja) | 2012-02-08 |
| JP2005519919A (ja) | 2005-07-07 |
| TW200302104A (en) | 2003-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dechavanne et al. | Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery | |
| Agnelli et al. | A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture | |
| Thery et al. | Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. | |
| Lindmarker et al. | Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis | |
| Torholm et al. | Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study | |
| Harenberg et al. | Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin | |
| Alfaro et al. | Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine | |
| Adams, Jr et al. | Studies of Org 10172 in patients with acute ischemic stroke | |
| AU2003205664B2 (en) | Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis | |
| US4820693A (en) | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage | |
| AU2003205664A1 (en) | Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis | |
| Wood et al. | Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis | |
| Hirsh et al. | The emerging role of low-molecular-weight heparin in cardiovascular medicine | |
| US20030092671A1 (en) | Antithrombotic composition | |
| HK1072361B (en) | Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis | |
| Vojvodić et al. | Absorption and excretion of pralidoxime in man after intramuscular injection of PAM-2CL and various cholinolytics | |
| Thompson‐Ford | Low‐Molecular‐Weight Heparin for the Treatment of Deep Vein Thrombosis | |
| Hyers | Heparin therapy: regimens and treatment considerations | |
| CARROLL et al. | Hypophosphatemia and Reye's syndrome | |
| EP1568372A1 (en) | Administration of enoxaparin sodium to patients with severe renal impairment | |
| WO1999004801A1 (en) | Use of sulfated glycosaminoglycans for treating of retinopathy | |
| Monreal et al. | Heparins, coumarin and bone density | |
| Nurmohamed et al. | No significant accumulation of dermatan sulfate (DS) during chronic use in hemodialysis patients | |
| WO2007013845A1 (en) | Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution | |
| AU2002333202A1 (en) | Antithrombotic compositions comprising low molecular wieght heparin and low molecular weight dermatan sulphate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: SANOFI-AVENTIS Free format text: FORMER NAME: SANOFI-SYNTHELABO |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |